Latest News

  • Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis Read More
  • Statement by Richard Pops, Chairman and CEO of Alkermes on the Annual CDC Report on Drug Overdose Deaths and Suicide Mortality in the United States Read More
  • Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With Schizophrenia Read More

Investors

ALKS investor relations
Learn more Learn More

Pipeline

patient focused CNS disorder treatments
See Our Approach See Our Approach

Working at Alkermes

career opportunities at Alkermes
Working at Alkermes Join Our Team